Publications in collaboration with researchers from Academic Medical Center (22)

2016

  1. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1056-1062

  2. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

    PLoS Medicine, Vol. 12, Núm. 4

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  3. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

    Journal of Hepatology, Vol. 59, Núm. 2, pp. 213-220

  2. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

  3. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study

    BMC Infectious Diseases, Vol. 13, Núm. 1

2012

  1. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy

    Journal of Infectious Diseases, Vol. 204, Núm. 5, pp. 741-752

  2. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)

    HIV Medicine, Vol. 12, Núm. 6, pp. 374-382

2010

  1. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

    AIDS, Vol. 24, Núm. 11, pp. 1667-1678

2009

  1. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression

    Journal of Acquired Immune Deficiency Syndromes, Vol. 50, Núm. 5, pp. 457-463

  2. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal

    Clinical Infectious Diseases, Vol. 48, Núm. 8, pp. 1138-1151

2008

  1. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

    AIDS, Vol. 22, Núm. 3, pp. 367-376

  2. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

    AIDS, Vol. 22, Núm. 16, pp. 2143-2153

2005

  1. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?

    Antiviral Therapy, Vol. 10, Núm. 7, pp. 779-790